^
    Back
    Association details:
    Biomarker:KIF5B-RET fusion
    Cancer:Small Cell Lung Cancer
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Onco Targets Ther
    Title:

    Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer

    Published date:
    11/29/2023
    Excerpt:
    NGS revealed the KIF5B-RET fusion in the C-SCLC tumor. The patient had a progression-free survival (PFS) surpassing 14 months after selpercatinib treatment, with ongoing clinical response in 4th-line treatment.
    DOI:
    https://doi.org/10.2147/OTT.S440610